Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients

NCT02016833 is registered in ClinicalTrials.gov with PX Biosolutions as lead sponsor.

NCT NCT02016833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02016833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients
Lead sponsor
PX Biosolutions
Phase
Observational
Overall status
Completed
Start date
October 31, 2013
Completion date
December 31, 2014
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, cervical cancer, cervical intraepithelial neoplasia, grade 3, chronic myeloid leukemia, ovarian serous adenocarcinoma, undifferentiated carcinoma of ovary